South Texans can participate in massive, national health program to change the future of healthcare
25 juil. 2022 08h30 HE
|
BioBridge Global
SAN ANTONIO, July 25, 2022 (GLOBE NEWSWIRE) -- South Texas Blood & Tissue has partnered with the National Institutes of Health’s All of Us Research Program, to recruit and engage participants in...
New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care
13 juin 2022 10h00 HE
|
Reveal Pharmaceuticals
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate in the brain and body of every patient,...
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
01 juin 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Inherent Biosciences, Inc. Awarded NIH SBIR Phase I Grant to Commercialize Innovative Diagnosis of Non-Obstructive Azoospermia (The Most Severe Form of Sperm Dysfunction)
13 avr. 2022 09h11 HE
|
Inherent Biosciences Inc
SALT LAKE CITY, April 13, 2022 (GLOBE NEWSWIRE) -- Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today announced an award from the National Institute of Child Health...
Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
29 mars 2022 13h04 HE
|
GreenLight Biosciences
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant...
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
02 mars 2022 06h00 HE
|
SAB Biotherapeutics, Inc.
NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
24 janv. 2022 15h52 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
11 janv. 2022 15h00 HE
|
Enterin Inc.
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
04 nov. 2021 07h00 HE
|
reMYND
Press Release reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company...
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
20 oct. 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...